Cargando…
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group
SUMMARY: Upper limb fractures (including wrist, forearm, and humerus) represent a significant burden among postmenopausal women with osteoporosis. Up to 7 years of treatment with denosumab resulted in an increase in bone mineral density and decrease in fractures in upper limb sites. INTRODUCTION: Up...
Autores principales: | Bilezikian, J.P., Lin, C.J.F., Brown, J.P., Wang, A.T., Yin, X., Ebeling, P.R., Fahrleitner-Pammer, A., Franek, E., Gilchrist, N., Miller, P.D., Simon, J.A., Valter, I., Zerbini, C.A.F., Libanati, C., Chines, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719332/ https://www.ncbi.nlm.nih.gov/pubmed/31201481 http://dx.doi.org/10.1007/s00198-019-05020-8 |
Ejemplares similares
-
Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease
por: Broadwell, Aaron, et al.
Publicado: (2020) -
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
por: Papapoulos, S., et al.
Publicado: (2015) -
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
por: Kendler, D. L., et al.
Publicado: (2018) -
Efficacy of teriparatide compared with risedronate on FRAX(®)-defined major osteoporotic fractures: results of the VERO clinical trial
por: Body, J.-J., et al.
Publicado: (2020) -
Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)